Efficacy and safety of aclidinium bromide/formoterol fumarate fixed-dose combinations compared with individual components and placebo in patients with COPD (ACLIFORM-COPD): a multicentre, randomised study

Aclidinium/formoterol is a twice-daily (BID) fixed-dose combination (FDC) in development for chronic obstructive pulmonary disease (COPD). The efficacy and safety of aclidinium/formoterol versus monotherapy and placebo in patients with COPD was assessed. In this 24-week double-blind, parallel-group,...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	BMC pulmonary medicine 2014-11, Vol.14 (1), p.178, Article 178
Hauptverfasser:	Singh, Dave, Jones, Paul W, Bateman, Eric D, Korn, Stephanie, Serra, Cristina, Molins, Eduard, Caracta, Cynthia, Gil, Esther Garcia, Leselbaum, Anne
Format:	Artikel
Sprache:	eng
Schlagworte:	Aged Chronic obstructive pulmonary disease Colleges & universities Comparative analysis Double-Blind Method Drug Combinations Drug therapy Drug therapy, Combination Dyspnea - etiology Female Forced Expiratory Volume Formoterol Fumarate - administration & dosage Formoterol Fumarate - agonists Hospitals Humans Laboratories Male Middle Aged Pharmaceutical industry Pulmonary Disease, Chronic Obstructive - complications Pulmonary Disease, Chronic Obstructive - drug therapy Pulmonary Disease, Chronic Obstructive - physiopathology Pulmonology Quality of Life Questionnaires Severity of Illness Index Tropanes - administration & dosage Tropanes - adverse effects Vital Capacity Writing
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	Aclidinium/formoterol is a twice-daily (BID) fixed-dose combination (FDC) in development for chronic obstructive pulmonary disease (COPD). The efficacy and safety of aclidinium/formoterol versus monotherapy and placebo in patients with COPD was assessed. In this 24-week double-blind, parallel-group, active- and placebo-controlled, multicentre Phase III study, patients (≥40 years, post-bronchodilator forced expiratory volume in 1 second [FEV1]/forced vital capacity
ISSN:	1471-2466 1471-2466
DOI:	10.1186/1471-2466-14-178